In 1994 was first approved for use in treating thalassaemia major in 1994. and had been licensed for use in Europe and Asia for many years while awaiting approval in Canada and the United States. On October 14, 2011, it was approved for use in the US under the FDA’s accelerated approval program.
^Wanless I, Sweeney G, Dhillon A, Guido M, Piga A, Galanello R, Gamberini M, Schwartz E, Cohen A (2002). "Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia". Blood100 (5): 1566–9. doi:10.1182/blood-2002-01-0306. PMID12176871.Full Text.